Microcap Ledger Protalix BioTherapeutics, Inc. $PLX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Hackensack, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 80,571,642 [10-Q 2026-08-12]
What the company doesAI summary of filing
Protalix BioTherapeutics is a commercial-stage biopharmaceutical company that develops and produces recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression platform. The company generates revenue from two marketed enzyme replacement therapies: Elelyso (taliglucerase alfa) for Gaucher disease, which it supplies to Pfizer for commercialization outside Brazil and to Fiocruz in Brazil, and Elfabrio (pegunigalsidase alfa) for Fabry disease, which it supplies to Chiesi for global commercialization. Protalix also has clinical-stage programs including PRX-115, a PEGylated uricase in Phase 2 development for uncontrolled gout, and PRX-119, a PEGylated DNase I in preclinical development for NETs-related diseases, along with preclinical research programs in rare renal indications. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $53.65M | $22.09M | $11.63M | $27.42M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $52.74M | −$6.60M | −$11.99M | $14.68M | [10-K 2026-03-18] |
| FY ended Dec 2024 | $53.40M | $2.93M | $8.67M | $19.76M | [10-K 2026-03-18] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 73,633,583 | [10-Q 2024-11-14] |
| 2025-03-14 | 78,032,585 | [10-K 2025-03-17] |
| 2025-05-01 | 79,607,115 | [10-Q 2025-05-09] |
| 2025-08-01 | 79,732,115 | [10-Q 2025-08-14] |
| 2025-11-01 | 80,421,181 | [10-Q 2025-11-13] |
| 2026-03-01 | 80,571,642 | [10-K 2026-03-18] |
| 2026-05-01 | 80,571,642 | [10-Q 2026-05-13] |
| 2026-08-01 | 80,571,642 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2025-04-28; declared effective 2025-08-22 [S-3 2025-04-28]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations |
| 2026-07-29 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-25 | 8-K | Shareholder vote results |
| 2026-05-21 | 8-K | Regulation FD disclosure |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-03-30 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-03-18 | 10-K | Annual report |
| 2026-03-18 | 8-K | Results of operations |
| 2026-03-09 | 8-K | Other events |
Alerts for $PLX
Email me when Protalix BioTherapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.